GlassScriptPhysician profile
Atul Shah
NPI 1851406227
$12,884.98
in general payments reported to CMS, 2019-2025
56 companies · $2,028 in 2025
The $2,028 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,340 · 2020: $1,619 · 2021: $2,041 · 2022: $1,783 · 2023: $2,034 · 2024: $2,041 · 2025: $2,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,102.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,770.73 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $942.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $826.51 | 2020-2025 | Qulipta, Ubrelvy, Vraylar |
| Amgen INC. | $807.40 | 2019-2025 | Repatha, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $591.49 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $585.05 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $568.50 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $560.68 | 2019-2022 | |
| Lilly USA, LLC | $559.29 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $467.01 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $426.87 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $390.92 | 2019-2023 | |
| Inari Medical, INC. | $389.49 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $346.51 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $318.05 | 2019-2024 | Eliquis, Camzyos |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atul Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.